Paradigm shift in the pharmacological management of periodontal diseases. - Wikidata - wikimedia - TriplyDB

Paradigm shift in the pharmacological management of periodontal diseases.

Paradigm shift in the pharmacological management of periodontal diseases.

http://www.wikidata.org/entity/Q37964882

about

Interdental brushing for the management of periodontal diseases and dental caries in adults Complement Involvement in Periodontitis: Molecular Mechanisms and Rational Therapeutic Approaches Emerging targets in lipid-based therapy Immunomicrobial pathogenesis of periodontitis: keystones, pathobionts, and host response Genetic and intervention studies implicating complement C3 as a major target for the treatment of periodontitis.Antagonistic effects of IL-17 and D-resolvins on endothelial Del-1 expression through a GSK-3β-C/EBPβ pathway The inflammophilic character of the periodontitis-associated microbiota Activation and resolution of periodontal inflammation and its systemic impact.Oral inflammatory diseases and systemic inflammation: role of the macrophage.An oral health optimized diet can reduce gingival and periodontal inflammation in humans - a randomized controlled pilot study.Local complement-targeted intervention in periodontitis: proof-of-concept using a C5a receptor (CD88) antagonist.Inhibition of GSK3 abolishes bacterial-induced periodontal bone loss in mice.Immune and regulatory functions of neutrophils in inflammatory bone loss.Complement inhibition in pre-clinical models of periodontitis and prospects for clinical application Neutrophil homeostasis and periodontal health in children and adults.Inflammatory reaction - communication of cells.Periodontal herpesviruses: prevalence, pathogenicity, systemic risk.Gene expression dynamics during diabetic periodontitis.Association between low-dose aspirin and periodontal disease: results from the continuous national health and nutrition examination survey (NHANES) 2011-2012.Elevated oral and systemic levels of soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) in periodontitis.Host modulation therapy with anti-inflammatory agents.Revisiting the Page & Schroeder model: the good, the bad and the unknowns in the periodontal host response 40 years later.Dietary supplementation with low-dose omega-3 fatty acids reduces salivary tumor necrosis factor-α levels in patients with chronic periodontitis: a randomized controlled clinical study.Fibroblast VEGF-receptor 1 expression as molecular target in periodontitis.

P2860

Q24198224-B56CAD46-05D7-4842-9ACF-116686E3BB92 Q26797414-B202C802-77E2-49C1-8693-72E830AD39C8 Q28655456-FF684F6B-EA7A-484D-A10A-454A06DFF3AE Q28658053-43704F5E-D2E7-4E9D-8098-0D2D92A9E8A5 Q30582298-278033EC-F122-4295-A362-7E863713B4E9 Q30664773-82C624C0-950A-446E-B6A2-F7C2EC998660 Q34514076-3BBB54B7-1102-4AD0-85F8-5344D2ECC92D Q35932966-9FDF7490-B85F-441D-A364-213D796386BE Q35963446-7BC8F0C2-6C29-4F24-B84E-C39B68ACFC70 Q36086494-14639368-E14E-4AA9-8E2D-DDA0578B8664 Q36417215-F9B5B6FF-91B3-4668-9B52-F2D77D34EE72 Q36434353-CB7AA6D7-5BF1-4F6C-9A51-D914EC7C50B9 Q36902096-E6B64C59-1087-4EE6-9246-D194F1A23B56 Q37180462-C3721598-F49D-41F4-B858-AA8D8862CE73 Q37594566-D590D1FE-BF40-4BBF-BA0D-1F8A5BBA0611 Q38100219-2A5D65D1-6231-4E34-9489-99FE4F7B992B Q38562419-F14BAF49-4C43-416C-90EE-5E08AAF90C40 Q41159150-ABACF2C5-EF10-40CF-87BD-4A14EC9F5429 Q41434526-002DE4D4-88E0-4580-922A-05B4D6853C3B Q43407960-66CA0232-2D48-4298-BD3F-679ACCD5FF8C Q48585276-C7C4E351-9AA8-4C88-9A29-40D27B3D516F Q50516275-57A8C6F0-AC6C-44DB-8A70-B24162CCBF46 Q50905023-1C0425D8-76EB-4A82-932E-3F38EA73ECB0 Q51542931-00C8360A-D593-4BA1-AE19-715B467064CF

P2860

Paradigm shift in the pharmacological management of periodontal diseases.

http://www.wikidata.org/entity/Q37964882

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh

2011年學術文章

@zh-hant

name

Paradigm shift in the pharmacological management of periodontal diseases.

@en

Paradigm shift in the pharmacological management of periodontal diseases.

@nl

type

label

Paradigm shift in the pharmacological management of periodontal diseases.

@en

Paradigm shift in the pharmacological management of periodontal diseases.

@nl

prefLabel

Paradigm shift in the pharmacological management of periodontal diseases.

@en

Paradigm shift in the pharmacological management of periodontal diseases.

@nl

P1433

Q37964882-DC8EF0CE-B58C-4EAE-A239-0799D9A4D21D

P1476

Q37964882-9C1B30AF-58BE-42CE-950B-08CED6957AB2

P2093

Q37964882-26D3D451-9A96-4391-9408-009246B75136

Q37964882-7DB7BEFF-92C8-4473-B10A-B1EB32BBA43C

Q37964882-D1B0D69B-4DA0-40BB-8B56-3696B89BF6D1

P2860

Q37964882-056F7105-029B-431A-82FE-FAF83B89219D

Q37964882-0589D426-EC5D-44C7-9AB5-E28E12401749

Q37964882-06C158A9-1FAC-4AB2-BB41-65A9E0461DD0

Q37964882-086ADB89-F327-4B31-96DA-65DF71428129

Q37964882-0F5B796D-2AA7-4AD7-8B0A-3FDE510B48F1

Q37964882-118FA343-C01C-4176-9B4C-145CEE4ABCCF

Q37964882-11E7027F-A195-4B49-930A-EBE4360B69F1

Q37964882-167E6BA4-4B0B-404E-9C40-4FE1EFB7B028

Q37964882-169E8854-9AAA-492E-9423-39A735548E8F

Q37964882-16F7620D-7B02-489F-8FD8-7ED6A68B4A17

P304

Q37964882-88EE351D-6447-4CF9-BEB3-AB60859E307D

P31

Q37964882-AED33C48-2E34-48FD-95E3-7F63C6EAF7B1

P356

Q37964882-6810074E-1DCA-41E0-A504-B26CE5E2B5AE

P478

Q37964882-D1BB862A-462D-4D9D-8E09-D1B16623D3BB

P577

Q37964882-634E878E-AE2E-425F-836D-1EC883C3417A

P698

Q37964882-E33DEE55-BAF0-4FAB-8838-D7305513973E

P921

Q37964882-06CADE9F-A071-423C-88C7-C7247816E8F1

P932

Q37964882-BA386BA7-0A7F-4E01-854B-818663E13C68

P356

P1433

Frontiers of Oral Biology

P1476

Paradigm shift in the pharmacological management of periodontal diseases.

@en

P2093

Alpdogan Kantarci

http://www.w3.org/2001/XMLSchema#string

Hatice Hasturk

http://www.w3.org/2001/XMLSchema#string

Thomas E Van Dyke

http://www.w3.org/2001/XMLSchema#string

P2860

A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease.

Neuroprotectin D1: a docosahexaenoic acid-derived docosatriene protects human retinal pigment epithelial cells from oxidative stress

cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase

Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions

Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals

Cyclooxygenase-2: molecular biology, pharmacology, and neurobiology

Studies on the mechanism of action of anti-inflammatory drugs. A paper in honour of John Vane

Inosine monophosphate and aspirin-triggered 15-epi-lipoxin A4 act in concert to regulate neutrophil trafficking: additive actions of two new endogenous anti-inflammatory mediators

Unorthodox routes to prostanoid formation: new twists in cyclooxygenase-initiated pathways

The contributions of aspirin and microbial oxygenase to the biosynthesis of anti-inflammatory resolvins: novel oxygenase products from omega-3 polyunsaturated fatty acids

P304

160-176

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1159/000329678

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P577

2011-11-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22142963

http://www.w3.org/2001/XMLSchema#string

P921

P932

4522924

http://www.w3.org/2001/XMLSchema#string